Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
2.520
+0.050 (+2.02%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Theraptc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
March 06, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...
Via
Benzinga
Esperion Therapeutics Stock Is Diving: What's Going On?
March 06, 2023
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
March 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.
Via
Benzinga
The Latest Analyst Ratings for Esperion Therapeutics
February 27, 2023
Via
Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
February 22, 2023
Via
Benzinga
Esperion Therapeutics's Earnings Outlook
February 20, 2023
Via
Benzinga
Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors
March 06, 2023
Via
Benzinga
Esperion Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
March 06, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
March 04, 2023
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Launches New Scientific Website
February 24, 2023
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
February 23, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
CLEAR Outcomes Company Update Call: Detailed Results Discussion
February 22, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
February 21, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
February 20, 2023
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
February 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
January 11, 2023
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
January 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Top Picks For 2023: Esperion
January 02, 2023
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick...
Via
Talk Markets
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
December 19, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 13, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in January Investor Meetings
December 13, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
December 07, 2022
Via
Benzinga
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
December 07, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Appoints Ben Halladay Chief Financial Officer
November 16, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics's Return On Capital Employed Insights
November 09, 2022
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12...
Via
Benzinga
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
November 09, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
November 02, 2022
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.